Cingulate has filed a notice of a Private Investment in Public Equity (PIPE) offering of securities to raise $7,500,000.00 in New Equity Investment.
According to filings with the U.S. Securities and Exchange Commission, Cingulate is raising $7,500,000.00 in new funding. About Cingulate: Cingulate Inc., a clinical-stage biopharmaceutical company, focuses on the development of product candidates for the treatment of attention-deficit/hyperactivity disorder. The company’s lead product candidates are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, and CTx-1302 (dextroamphetamine) for the treatment of attention-deficit/hyperactivity disorders intended for children, adolescents, and adults. It also focuses on developing CTx-2103 for the treatment of anxiety disorders. The company was founded in 2012 and is headquartered in Kansas City, Kansas.
To learn more about Cingulate, visit http://www.cingulate.com/
Contact:
Shane Schaffer, Chief Executive Officer
913-942-2300
SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.